Hemostasis in normotensive and hypertensive men: Results of the procam study

Journal of Hypertension

Volumn 16, Issue 7, 1998, Pages 918-922

  Junker, Ralf ^a   Heinrich, Jürgen ^b   Schulte, Helmut ^b   Erren, Michael ^b   Assmann, Gerd ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Institut für Arterioskleroseforschung an der Westfä   (Germany)

Author keywords

Blood pressure; Cardiovascular risk factor; Coagulation; Fibrinolysis; Hypertension; PROCAM study

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION FUNCTION; DIASTOLIC BLOOD PRESSURE; EUGLOBULIN LYSIS TEST; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SYSTOLIC BLOOD PRESSURE;

EID: 0031870695     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/00004872-199816070-00004     Document Type: Article

References (39)

1. van de Loo J. Circulating factors of the haemostatic systems as indicators of increased or reduced coronary risk. Br J Haematol 1995; 91:777-782.
2. Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997; 17:1539-1544.
3. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii:533-537.
4. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14:54-59. [published erratum Arterioscler Thromb 1994; 4:1392].
5. Cooper J, Douglas AS. Fibrinogen level as a predictor of mortality in survivors of myocardial infarction. Fibrinolysis 1991; 5:105-108.
6. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, et al. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arterioscler Thromb 1992; 12:1063-1070.
7. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66:351-355.
8. Thompson SG, Fechtrup C, Squire E, Heyse U, Breithardt G, van de Loo JC, et al. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996; 16:357-362.
9. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332:635-641.
10. Cortellaro M, for the PLAT Study Group. Antithrombin III and arterial disease. Lancet 1991; 338:1525-1526.
11. Meade TW, Cooper J, Miller GJ, Howarth DJ, Stirling Y. Antithrombin III and arterial disease. Lancet 1991; 338:850-851.
12. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii:3-9.
13. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153:598-615.
14. Zanchetti A, Chalmers JP, Arakawa K, Gyarfas I, Hamet P, Hansson L, et al. The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Blood Press 1993; 2:86-100.
15. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227:273-278.
16. Glueck CJ, Glueck HI, Hamer T, Speirs J, Tracy T, Stroop D. Beta blockers, Lp(a), hypertension, and reduced basal fibrinolytic activity. Am J Med Sci 1994; 307:317-324.
17. Donders SH, Lustermans FA, van Wersch JW. Coagulation factors and lipid composition of the blood in treated and untreated hypertensive patients. Scand J Clin Lab Invest 1993; 53:179-186.
18. Eliasson M, Evrin PE, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. J Clin Epidemiol 1994; 47:513-524.
19. Balleisen L, Assmann G, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population II. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. Thromb Haemost 1985; 54:721-723.
20. Cigolini M, Targher G, Seidell JC, Tonoli M, Schiavon R, Agostino G, et al. Relationships of blood pressure to fibrinolysis: influence of anthropometry, metabolic profile and behavioural variables. J Hypertens 1995; 13:659-666.
21. Smith WC, Lowe GD, Lee AJ, Tunstall Pedoe H. Rheological determinants of blood pressure in a Scottish adult population. J Hypertens 1992; 10:467-472.
22. Lee AJ, Lowe GD, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J 1993; 69:338-342
23. Koenig W, Wund M, Ernst E, Keil U, Rosenthal J, Hombach V. Association between plasma viscosity and blood pressure. Results from the MONICA-project Augsburg. Am J Hypertens 1991; 4:529-536.
24. Fowkes FG, Lowe GD, Rumley A, Lennie SE, Smith FB, Donnan PT. The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J 1993; 14:597-601.
25. Phillips GB, Jing TY, Resnick LM, Barbagallo M, Laragh JH, Sealey JE. Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens 1993; 11:699-702.
26. Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell-Omo G, Catapano G, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344:14-18.
27. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T, et al. Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Arterioscler Thromb Vasc Biol 1996; 16:455-461.
28. Blann AD, Naqvi T, Waite M, McCollum CN. von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993; 7:107-111.
29. Jones CJ, Singer DR, Watkins NV, MacGregor GA, Caro CG. Abnormal arterial flow pattern in untreated essential hypertension: possible link with the development of atherosclerosis. Clin Sci Colch 1990; 78:431-435.
30. Wall U, Jern C, Bergbrant A, Jern S. Enhanced levels of tissue-type plasminogen activator in borderline hypertension. Hypertension 1995; 26:796-800.
31. Trifiletti A, Barbera N, Pizzoleo MA, Lasco A, Lucifora S, Leone G, et al. Haemostatic variables in arterial hypertension. Haemostasis 1995; 25:237-240.
32. Jeng JR, Sheu WH, Jeng CY, Huang SH, Shieh SM. Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 1996; 9:484-490.
33. Jansson JH, Johansson B, Boman K, Nilsson TK. Hypofibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med 1991; 229:309-316.
34. DeSouza CA, Dengel DR, Rogers MA, Cox K, Macko RF. The fibrinolytic system is not impaired in older men with hypertension. Hypertension 1996; 27:1053-1058.
35. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol 1992; 70:733-737.
36. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in the elderly. Hypertension 1994; 23:275-285.
37. Jespersen J, Astrup T. A study of the fibrin plate assay of fibrinolytic agents. Haemostasis 1983; 3:301-315.
38. Lip GY, Beevers DG. Abnormalities of rheology and coagulation in hypertension. J Hum Hypertens 1994; 8:693-702.
39. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320:1165-1172.